Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates
and virtually on May 11-12, 2022. The data was featured in a poster presentation entitled "AAV204, a Novel AAV Capsid, Demonstrates Superior Macular Transduction Following Para-Retinal Administration in Non-Human Primates." AAV204, a novel adeno-associated virus (AAV) capsid from Abeona's in-licensed AIM(TM) capsid library, has previously been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates. The purpose of the current study was to evaluate in non-human primates transduction levels in the macula and optic nerve following administration of AAV204 directly into the vitreous of the eye by para-retinal administration, a recently-developed method, which unlike subretinal administration does not create a retinal detachment.